Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309855 · ClinicalTrials.gov registry record · Phase 1
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00309855: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00309855 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309855, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual function.
Primary Outcome
GH will be measured 4 different times mornings within 16-21 days following the first testosterone injection (day 1).
Interventions
- DRUG Placebo
- DRUG Testosterone
- DRUG Anastrazole
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
What the finished NCT00309855 record still lists
NCT00309855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00309855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00309855 about?
NCT00309855 is a clinical study titled "Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men". This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Bo...
What is the current status of trial NCT00309855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2005-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00309855?
The interventions under investigation include: Placebo (DRUG), Testosterone (DRUG), Anastrazole (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00309855?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00309855's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia